Hamilton Health Sciences Corporation
hamiltonhealthsciences.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
239
Active
34
Phase 3
46
Total enrollment
213,341
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Semaglutide Pen Injector | — | — | — | — | — | 1 | |
| Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution | — | — | — | — | — | 1 | |
| Sham Comparator | — | — | — | — | — | 1 | |
| Vancomycin | — | — | — | 3 | |||
| Cefazolin | — | — | — | — | 2 | ||
| Chlorhexidine Gluconate | — | — | — | — | — | 1 | |
| Vancomycin Hydrochloride | — | — | — | — | — | 1 | |
| Before CPB Tranexamic Acid | — | — | — | — | — | 1 | |
| After CPB Tranexamic Acid | — | — | — | — | — | 1 | |
| Before CPB Placebo | — | — | — | — | — | 1 | |
| After CPB Placebo | — | — | — | — | — | 1 | |
| PEG 3350 | — | — | — | — | — | 1 | |
| Levetiracetam | — | — | — | — | — | 1 | |
| Chemotherapy/Radiation | — | — | — | — | — | 1 | |
| Extra 600mg of Rifampicin | — | — | — | — | — | 1 | |
| Colchicine 0.5 MG | — | — | — | — | — | 1 | |
| Colchicine placebo | — | — | — | — | — | 1 | |
| Thiamine Mononitrate 300 mg | — | — | — | — | — | 1 | |
| Desmopressin Injectable Solution | — | — | — | — | — | 1 | |
| Tranexamic Acid Injectable Product | — | — | — | — | — | 1 | |
| Metformin | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| Tideglusib | — | — | — | — | — | 1 | |
| mFOLFIRINOX | — | — | — | — | — | 1 | |
| Gemcitabine / Nab-paclitaxel | — | — | — | — | — | 1 | |
| Standard Dose - Ibuprofen oral suspension | — | — | — | — | — | 1 | |
| Precision Dose - Ibuprofen oral suspension | — | — | — | — | — | 1 | |
| Colchicine | — | — | — | — | 2 | ||
| Fecal Microbiota Transplant | — | — | — | — | — | 1 |
Next readouts
- 2025-12-12
- 2026-01-01
- 2026-03
- 2026-04
- 2026-05-31
- 2026-07
- 2026-07-31
- 2026-12-30
- 2027-02
- 2027-02-01
Top conditions
- Asthma8
- Coronary Artery Disease7
- Breast Cancer7
- Hypertension6
- Bleeding5
- Cardiovascular Disease5
- Venous Thromboembolism5
- Heart Failure5
Frequently asked questions about Hamilton Health Sciences Corporation
- How many clinical trials does Hamilton Health Sciences Corporation have on ClinicalTrials.gov?
- Hamilton Health Sciences Corporation is listed as the lead sponsor on 239 clinical trials in ClinicalTrials.gov, 34 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hamilton Health Sciences Corporation's trials are in Phase 3?
- 46 of Hamilton Health Sciences Corporation's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does Hamilton Health Sciences Corporation focus on?
- Hamilton Health Sciences Corporation's most-studied conditions on ClinicalTrials.gov are Asthma, Coronary Artery Disease, Breast Cancer, Hypertension, Bleeding.
- When are Hamilton Health Sciences Corporation's next clinical trial readouts?
- Hamilton Health Sciences Corporation has 10 upcoming primary-completion readouts tracked here; the soonest is “Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery”, expected around 2025-12-12.